Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid

[1]  C R Jack,et al.  Serial MRI and CSF biomarkers in normal aging, MCI, and AD , 2010, Neurology.

[2]  Nick C Fox,et al.  11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.

[3]  K. Blennow,et al.  Pittsburgh Compound-B and Alzheimer’s Disease Biomarkers in CSF, Plasma and Urine: An Exploratory Study , 2010, Dementia and Geriatric Cognitive Disorders.

[4]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[5]  Mark A Mintun,et al.  Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. , 2009, Archives of neurology.

[6]  A. Fagan,et al.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.

[7]  A. Fagan,et al.  Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease , 2009, EMBO molecular medicine.

[8]  J O Rinne,et al.  Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls , 2009, Neurology.

[9]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[10]  Nelleke Tolboom,et al.  Relationship of Cerebrospinal Fluid Markers to 11C-PiB and 18F-FDDNP Binding , 2009, Journal of Nuclear Medicine.

[11]  Henrik Zetterberg,et al.  Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease , 2009, PloS one.

[12]  A. Drzezga,et al.  Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid , 2009, Biological Psychiatry.

[13]  Cindee M. Madison,et al.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.

[14]  G. Frisoni,et al.  In vivo mapping of amyloid toxicity in Alzheimer disease , 2009, Neurology.

[15]  Joseph Hilbe,et al.  Data Analysis Using Regression and Multilevel/Hierarchical Models , 2009 .

[16]  D. Galimberti,et al.  Faculty Opinions recommendation of Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. , 2009 .

[17]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[18]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[19]  H. Soininen,et al.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.

[20]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[21]  Sakari Savolainen,et al.  Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. , 2008, Archives of neurology.

[22]  H. Engler,et al.  PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[23]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[24]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[25]  A. Verma,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study , 2008 .

[26]  C. Jack,et al.  11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment , 2008 .

[27]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[28]  M. Viitanen,et al.  PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment , 2007, Neurology.

[29]  Paul Maruff,et al.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.

[30]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[31]  Sander Greenland,et al.  Multiple-imputation for measurement-error correction. , 2006, International journal of epidemiology.

[32]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[33]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[34]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[35]  Nicole A. Lazar,et al.  Statistical Analysis With Missing Data , 2003, Technometrics.

[36]  W. Klunk,et al.  Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. , 2003, Journal of medicinal chemistry.

[37]  K. Blennow,et al.  CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.

[38]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[39]  D. Rubin,et al.  Statistical Analysis with Missing Data. , 1989 .

[40]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[41]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.